Ritonavir
- 1 October 1996
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 52 (4), 541-546
- https://doi.org/10.2165/00003495-199652040-00007
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538).1996
- Current Knowledge and Future Prospects for the Use of HIV Protease InhibitorsDrugs, 1996
- Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.1996
- Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, RitonavirThe Journal of Infectious Diseases, 1996
- A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 InfectionNew England Journal of Medicine, 1995
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.Proceedings of the National Academy of Sciences, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995